logo

CDC considers narrowing its Covid-19 vaccine recommendations

CNN16-04-2025

Source: CNN
The US Centers and Disease Control and Prevention is considering recommending annual Covid-19 shots to those who are older or who have compromised immune function, rather than the current blanket recommendation for everyone 6 months of age and older.
The change would more closely align the US with guidance given in other countries. Unlike countries such as the United Kingdom, Canada and Australia, the US alone recommends an annual Covid-19 vaccine for healthy younger adults and children. The World Health Organization also doesn't routinely recommend annual Covid-19 vaccines for healthy adults under 65 or healthy children.
On Monday, a panel of independent experts that advises the CDC on its vaccine recommendations, called the Advisory Committee on Immunization Practices, weighed the pros and cons of moving the US away from a blanket recommendation that most people get an updated Covid-19 shot every year and toward a more nuanced, risk-based recommendation.
Members of the Covid-19 vaccine work group said they began studying the policy change in November.
Under a risk-based recommendation, the CDC would continue to recommend two doses of Covid-19 vaccines each year for older adults — those over 65 — and to anyone with weakened immune function.
It may also consider recommending annual vaccination for adults and children who are at high risk of Covid-19 disease because they have a higher risk of being exposed to it. Those groups could include people like health-care workers or children in day care.
There was also strong support for a statement in the recommendation to say that anyone who wanted to get a Covid-19 vaccine could still get one, even if they didn't fit into a higher-risk category.
A risk-based recommendation would be more complicated to communicate to the public and potentially trickier to implement than a universal recommendation, and some members of the full committee said they'd be against it for that reason.
'I guess I'm surprised that we're considering a risk-based recommendation, which in general, we have not had a lot of success with implementing in the US,' said committee member Dr. Denise Jamieson, dean of the Carver College of Medicine at the University of Iowa.
Jamieson said she also worried that some people could lose insurance coverage for their Covid-19 vaccines if the recommendation was softened for some groups.
It's also not clear where the committee might land on underlying health conditions and who would be considered at higher risk based on a pre-existing condition, such as diabetes or heart or lung diseases.
An analysis of data based on the CDC's list of conditions that increase the risk for severe disease from a Covid-19 infection found that 74% of adults have at least one health condition that puts them at risk.
And even though Covid is no longer causing the same kind of punishing waves of illness and death as it once did, it was still the 10th leading cause of death among adults in 2023. From September 2023 through August 2024, it caused roughly 40,000 deaths in the US.
'Covid is still a fairly dangerous disease and very, very common,' said committee member Dr. Jamie Loehr, who runs a family practice clinic in Ithaca, New York.
Loehr said he wondered how feasible it might be to implement a risk-based recommendation and what message it might send to the public.
'Even though I'm in favor of a risk-based recommendation, I still have my hesitations,' he said.
Others worried that exempting healthy adults might make long Covid more common. Studies have shown that vaccination cuts the risk of developing the condition, which affected more than 9 million adults and children in 2023, according to national surveys.
'What I would like to see is modeling around long Covid,' said committee member Dr. Oliver Brooks, the chief medical officer of Watts Healthcare Corp. in Los Angeles. 'My primary concern through all of this at this point is long Covid.'
Though there was concern that risk-based recommendations would decrease vaccination, others pointed out there's no proof that's true.
'There's not clear evidence at all that risk-based approaches are less effective,' said committee member Dr. Noel Brewer, a professor of public health at the University of North Carolina. 'The data supporting that claim are not really there.'
On the whole, members of the committee who have studied the question most closely said they favored switching to risk-based recommendations.
As of April, more than three-quarters of the working group on the Covid-19 vaccine recommendations for this coming fall and winter favored risk-based recommendations, though they don't plan to formally vote on the policy change until the next meeting, which is scheduled for June.
See Full Web Article

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

H5N1 bird flu ‘capable of airborne transmission'
H5N1 bird flu ‘capable of airborne transmission'

Yahoo

time33 minutes ago

  • Yahoo

H5N1 bird flu ‘capable of airborne transmission'

H5N1 bird flu is capable of spreading through the air, a new animal study from the US Centres for Disease Control (CDC) has found. H5N1 was believed to spread primarily through direct contact with infected animals or their bodily fluids, but the new findings suggest it can also be transmitted through respiratory droplets and aerosol, raising concerns about its ability to cause a future pandemic. The study, published in Emerging Infectious Diseases, was based on a sample of H5N1 extracted from a dairy worker in Michigan who contracted the virus last year. The CDC scientists then used this sample to infect a group of ferrets, which are considered a 'gold standard' in flu research due to the similarity between their respiratory system and that of human. The infected animals were placed in close proximity to six other healthy ferrets and observed for three weeks. Within 21 days, three of the previously uninfected ferrets had contracted H5N1 – without any direct physical contact – indicating that the virus can travel through the air through a 'respiratory droplet transmission model'. The researchers also collected aerosol samples from the air surrounding the ferrets, and found infectious virus and viral RNA to be present, indicating that H5N1 can, like Covid-19, be transmitted through both respiratory droplets and aerosols – smaller particles that can travel longer distances and remain suspended in the air for extended periods. Respiratory droplets, on the other hand, are larger and do not travel as far in the air, requiring closer contact with an infected person for transmission. Since 2024, at least 70 people in the US have been infected with H5N1, the majority of them workers on poultry or dairy farms where the virus was present. Bird flu has spread to more than 1,000 dairy farms across the country over the past year and is now endemic among US cattle. 'This study is important as it provides yet more evidence that the H5N1 influenza virus that is circulating in dairy cattle in the USA is, in principle, capable of respiratory transmission,' Prof Ed Hutchinson, Professor of Molecular and Cellular Virology, MRC-University of Glasgow Centre for Virus Research told The Telegraph. '[The study] does this using experimental animals that experience and transmit influenza in similar ways to humans, so it warns us of what the virus could do in humans under the right circumstances,' Prof Hutchinson added. The study's authors warned that their findings underline the 'ongoing threat to public health' H5N1 poses, emphasising the need for 'continual surveillance and risk assessment… to prepare for the next influenza pandemic'. Most human cases reported in the US so far have resulted from direct physical contact with sick animals or their fluids, including cow's milk. But experts have warned that, as H5N1 continues to infect animal populations and 'jump' to humans, it is only a matter of time before the virus undergoes the mutations necessary to spread effectively from person to person. 'Because avian H5N1 viruses cross the species barrier and adapt to dairy cattle, each associated human infection presents further opportunity for mammal adaptation,' the study's authors said. Protect yourself and your family by learning more about Global Health Security Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

Why Trump turned against ‘gold standard' mRNA vaccines
Why Trump turned against ‘gold standard' mRNA vaccines

Yahoo

timean hour ago

  • Yahoo

Why Trump turned against ‘gold standard' mRNA vaccines

President Trump's administration has slammed the brakes on development of messenger RNA (mRNA) vaccines, which proved their lifesaving potential during the COVID-19 pandemic but have come under increasing scrutiny among skeptics of mainstream science. The vaccines marked a breakthrough in medical technology, drastically reducing the timeline for development of targeted vaccines and even showing promise in cancer research. Trump called mRNA the 'gold standard' when he rolled out the first COVID-19 vaccines. But now they are under assault by Trump's Health and Human Services (HHS) secretary, longtime anti-vaccine advocate Robert F. Kennedy Jr., and his allies in the 'make America healthy again' movement. HHS in late May canceled $766 million awarded to Moderna through the Biomedical Advanced Research and Development Authority (BARDA) to develop a potential mRNA vaccine for bird flu. HHS spokesperson Andrew Nixon said of the decision, 'This is not simply about efficacy — it's about safety, integrity, and trust.' 'The reality is that mRNA technology remains under-tested, and we are not going to spend taxpayer dollars repeating the mistakes of the last administration, which concealed legitimate safety concerns from the public,' he added. Unlike traditional vaccines that contain fragments or weakened versions of a virus, mRNA vaccines send messenger ribonucleic acid into cells to teach the immune system to recognize proteins connected to virus cells. According to Joseph Varon, president and chief medical officer of the Independent Medical Alliance (IMA), the concerns for mRNA vaccine skeptics are the expedited timeline and conditions in which the COVID-19 vaccine was approved. 'The biggest concern is that this rushed treatment still remains in use, even under an Emergency Use Authorization in some cases. It needs to be sent back through proper studies and vetting,' Varon told The Hill. 'There needs to be an established database of vaccine injuries that can be accurately quantified with full transparency, without politics or big money pressure influencing the data,' he added. 'There's a growing body of peer-reviewed studies that indicate the spike proteins are causing havoc in certain recipients.' The IMA, previously known as Front Line COVID-19 Critical Care Alliance, launched a campaign in support of Kennedy's nomination to be HHS secretary. The group drew controversy when its founders promoted ivermectin as a 'miracle drug' for COVID-19. Myocarditis, or inflammation of the heart muscle, is of particular concern among mRNA vaccine opponents. An analysis published in 2022 found that myocarditis occurred in about 31.2 cases per 1 million second doses of the Moderna COVID-19 vaccine, or 0.003 percent. Rates of myocarditis are significantly higher among people with COVID-19 infections than immunizations, however. The development of the COVID-19 mRNA vaccine was aided by the Trump administration's Operation Warp Speed, something Trump has boasted about at numerous points. In remarks in December 2020, the same month the first COVID-19 vaccines were deployed, Trump praised Operation Warp Speed's ability to develop a SARS-CoV-2 vaccine at a 'breakneck speed,' adding 'the gold standard vaccine has been done in less than nine months.' Though research on mRNA and its potential uses has been ongoing for decades, use of the vaccines in humans is relatively new. The first mRNA vaccine candidate tested in humans was for rabies in 2013, but it wouldn't be until the COVID-19 pandemic in 2020 that this technology would achieve commercial viability and widespread use. To Kennedy, this is too much of a coincidence. In his book 'The Wuhan Cover-Up: And the Terrifying Bioweapons Arms Race,' published in 2023, Kennedy suggests it was more than just happenstance that allowed for the deployment of Moderna's mRNA technology to coincide with the global pandemic. He pointed to a meeting attended by Dr. Anthony Fauci and former BARDA Director Rick Bright in which the officials met with virologists months before the COVID-19 pandemic broke out. The fact that attendees discussed the need for innovation in influenza research and vaccines became a point of conspiracy online. Kennedy noted that Bright called for something 'completely disruptive, that's not beholden to bureaucratic strings and processes,' writing, '[Bright] hinted that only a global crisis — like a pandemic — could induce government and industry to commit the billions of dollars necessary to create a new generation of 'plug-and-play' mRNA vaccines.' In the conversation Kennedy references, Bright was discussing the challenges of making influenza research 'sexy' for Ph.D. and postdoctoral students, surmising that something 'completely disruptive' would be needed to incite excitement in the field. Proponents of the mRNA technology point to its deployment in the COVID-19 pandemic and its role in reducing transmission as evidence of safety and efficacy. 'In the U.S., you know, we have a lot of real-world experience now with huge numbers of doses given. We have been following for significant or serious adverse events for a long time, and the rate of those serious adverse events is on par with what we see for other vaccines,' E. John Wherry, director of the Institute for Immunology and Immune Health at the University of Pennsylvania, said of mRNA vaccines. As Wherry notes, all vaccines have adverse side effects, but their safety compared with the diseases they inoculate against is 'incontrovertible.' And while critics take issue with the speed at which mRNA vaccines are developed, Wherry said this difference is precisely what sets these shots apart from older generations. 'mRNA vaccines have a couple of key benefits or features that really stand out compared to other vaccine platforms. One, they can be generated very, very quickly. So, you can adapt to changes very rapidly. This is much easier with an mRNA vaccine, where the COVID strain or flu strain mutates and changes from year to year,' Wherry said. 'The second is that it's relatively simple. So, we don't have to worry about, you know, impurities in, you know, an egg-grown vaccine or a cell-based grown vaccine synthesizing mRNA. There are very few components that go into it, and it can be synthesized with high purity.' Such mRNA vaccines are also potentially applicable for numerous conditions or even multiple different strains of the same virus, giving it more flexibility than traditional vaccinations. 'So, there are substantial benefits in flexibility, in speed, in simplicity of manufacturing and that probably also affects the cost of goods at the end of the day, which is perhaps a last advantage,' Wherry added. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store